Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients
Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients
This study evaluates the effect of recombinant human erythropoietin (rHuEPO) on the
 neovascularization of pediatric moyamoya disease patients. rHuEPO will be administrated
 during perioperative period of the first revascularization surgery. Primary outcome
 (Incidence of Good postoperative MCA territory revascularization by cerebral angiography)
 will be evaluated after 3-6 month of revascularization surgery.
Inclusion Criteria:

 -  Pediatric Moyamoya patients scheduled for the first revascularization surgery

 Exclusion Criteria:

 -  Hypersensitivity or contraindication to rHuEPO

 -  History of Unstable hypertension, Hypertensive encephalopathy, Thrombosis

 -  Primary intracerebral hemorrhage (ICH), Subarachnoid hemorrhage (SAH), Arterio-venous
 malformation (AVM), Cerebral aneurysm, or cerebral neoplasm

 -  History of seizure

 -  Hemoglobin >16 mg/dl

 -  Prolonged PT (PT > 15.5 seconds, PT INR > 1.2) or Prolonged aPTT (> 40 seconds)

 -  Thrombocytopenia (platelet count < 100,000/microL), Thrombocytosis (platelet count >
 400,000/microL), Neutropenia (absolute neutrophil count (ANC) < 1500/microL)

 -  Abnormal kidney function (Creatinine> 2.0 mg/dl, History of dialysis)

 -  Abnormal hepatic function (aspartate transaminase> 80 unit/L, alanine
 aminotransferase> 80 unit/L)